Three baseball-related SPACs have attractive potential, but when will they reward investors?
It's the type of transition the Biden team probably would put its antitrust lawyers on to squelch, again leaving Intel with no quick fix.
Here's my answer to a tough question.
Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.
Plus, the chart of Tesla indicates it's time to be wary if you're in the stock at present.
However, shares of the maker of agricultural and construction equipment still could see a period of sideways price action for a while.
Shares of the SPAC that soon will be the vehicle to take e-commerce grocery platform Boxed public have firmed of late.
The insurer's recent sale of a chunk of its business has led the company to share in the proceeds with its shareholders.
I still believe TR would command a solid premium in an acquisition, but I'm not holding my breath.
The cannabis biotech company explains why the acquisition of MagicMed makes sense, additional capital raises and the Psybrary.